This is the continuation of the good development trend of 20 19. In 20 19, the group achieved sales revenue of 23 billion yuan, paid taxes of 2.3 billion yuan, and exported 6150,000 dollars, ranking eighth in the top 100 list of China pharmaceutical industry in 20 18.
A series of eye-catching figures highlight the strong momentum of Qilu Pharmaceutical Group's high-quality development. The two strategies of innovation-driven and internationalization have been continuously implemented, and the concept of green development empowers sustainable development. Qilu pharmaceutical group made three arrows in unison and ran out of the "acceleration" of high-quality development.
Pay attention to the research and development of urgently needed drugs
Stimulate the power of innovation
Since 20 19, Qilu Pharmaceutical has developed 14 drugs, among which abiraterone, paclitaxel albumin for injection and lenadouan are all important drugs in related therapeutic fields.
2065 438+09- 12, Qilu Pharmaceutical successfully developed and marketed bevacizumab, the first biologically similar drug in China, and became a hot spot in the domestic pharmaceutical industry.
Qilu Pharmaceutical has been conscientiously implementing the central and local arrangements and requirements, focusing on the pharmaceutical industry, making every effort to steadily promote the company's production and operation, especially continuously strengthening scientific and technological innovation, continuously providing drugs urgently needed in clinic, deeply participating in actively promoting the reform of traditional Chinese medicine and achieving more results.
The QL-006 project of the group is suitable for the first treatment patients with ALK positive and those who have used 1 or more ALK inhibitors, which can solve the problem that there is no drug available for patients with ROS 1 mutation. Its safety is obviously better than that of similar therapeutic drugs, and its effective rate is increased by 20% on the basis of existing drugs, filling the gap in China.
The study of drug consistency can improve the safety and effectiveness of drugs and ensure the safety and effectiveness of people's medication. Qilu Pharmaceutical actively participated in the national drug consistency evaluation. Since March last year, 18 products have passed or are considered to have passed the conformity evaluation, and 28 drugs have passed the evaluation, leading the country. These overvalued products are all kinds of drugs urgently needed in clinic.
A large number of products passed the consistency evaluation, which laid a solid foundation for the Group to actively participate in the national centralized drug procurement and play the leading role of leading enterprises in the industry. In September of 20 19 and February of 19, Qilu Pharmaceutical participated in the national centralized drug procurement twice, and nine products won the bid, which greatly reduced the drug price, greatly reduced the burden on patients and saved the expenditure of the national medical insurance fund. At the same time, it has contributed to the smooth implementation of this major reform that benefits the country and the people, and has been well received by the National Medical Insurance Bureau and all walks of life.
At the same time, since 20 19, many major projects of the company have made good progress, providing new impetus for the next development.
The first phase of Qilu Pharmaceutical Dongjia Preparation Park project with a total investment of 5.5 billion yuan will soon be completed and put into operation. Relying on the advantages of Qilu Antie Company as the largest cephalosporin production base in the world, the industrial chain will be extended to the preparation terminal to build an internationally influential cephalosporin raw material medicine and preparation production base.
The first phase of the green biological pesticide project in Arun Banner, Inner Mongolia with an investment of 3.5 billion yuan will also be completed and put into operation in the second half of this year. This product is widely used in the development of green agriculture and grain storage, which will be very beneficial to improve the food safety level in China.
In addition, a number of high-end medical projects in Jinan, Dezhou and other places in Shandong are also advancing rapidly. These projects involve high-end biopharmaceuticals, chemicals for human use, high-end agricultural and veterinary drugs and other fields, which will greatly boost the company's performance and local economy after being put into production one after another. At the same time, because these projects are all high-tech projects, they will also provide a steady stream of new kinetic energy for the adjustment, development, transformation and upgrading of local industrial structure.
Sword refers to "global good" and "global new"
Become a global brand power
In recent years, Qilu Pharmaceutical has continuously increased its efforts to explore the international market, especially for international high-end markets such as Europe, America and Japan, and has become the main direction of pharmaceutical products.
Qilu Pharmaceutical Group has established a quality management system in line with international standards, and is the first enterprise in China to pass the British FDA, EDQM and MHRA aseptic product certification. The product structure of the group is scientific and complete, with the characteristics of wide treatment field and series products. Products are exported to more than 70 countries and regions around the world, and cephalosporin series, bactam series and other 10 raw materials have the first global market share. Preparation products are exported to countries with laws and regulations such as North America, Japan and Australia, and it is the only enterprise in China that exports commercial packaged injection products to Japan. Up to now, 14 pharmaceutical products have been exported to the United States, and in 20 19, the number of pharmaceutical products exported to the United States exceeded10000000 tablets, up about 160% year-on-year, of which injections accounted for about 50%. Cephalosporin series ranks first in the market share in Australia.
Recently, Qilu Antie Pharmaceutical Co., Ltd. obtained the CEP certificate (European Pharmacopoeia Applicability Certificate) issued by the European Union EDQM, which indicates that the company's cefaclor products have obtained the market access qualification of EU member States. This is the 12 CEP certificate obtained by Qilu 'an for the company, which adds another big boost to the company's competitiveness in the European market.
It is reported that in the first two months of this year, Qilu Pharmaceutical exported 33.29 million tablets to the United States, a substantial increase of 195% compared with the same period last year, maintaining the strong growth trend of exports to the United States since last year. Qilu Pharmaceutical's exports to the United States are characterized by expanding varieties, increasing shipments and rapidly increasing market share. Up to now, Qilu Pharmaceutical has exported 13 preparation products to the United States. Six products ranked in the top three in market share, among which 1 product ranked first with 44% market share. The influence of Qilu pharmaceutical products in the American market is also expanding, and it has become "Made in China" recognized by end customers. In 20 19, the market share of all products in the United States increased compared with the previous year, and six of them increased significantly.
In terms of export this year, the Group achieved a cumulative year-on-year growth of 12. 1%, and countries with high-end supervision market for preparation export continued to maintain a good development momentum. The export of preparations to the United States, Europe, Japan and other countries and regions increased by more than 20% year-on-year.
From "yes" to "no" is the key to achieving high-quality development. In terms of drug research and development, Qilu Pharmaceutical has continuously listed the drugs urgently needed in clinic, constantly breaking the monopoly of foreign giants, and at the same time fully promoting the research and development of innovative drugs with global independent intellectual property rights. Relying on the five R&D platforms linked by China and the United States, the Group has combined independent research and development with foreign cooperation, accelerated the promotion of more than 50 projects, aimed at "globally good" and "globally new" drugs, and aimed at global simultaneous listing. Among them, five have entered clinical trials, and there will be 10 applications for IND this year, and more than 40 applications for IND in the next five years.
Among them, PSB205 project PD 1/CTLA-4 is the "golden partner" of combined immunotherapy which has been proved by large-scale clinical practice. Qilu Pharmaceutical has been approved by the FDA of the United States to carry out clinical research in the United States 10 institutions, and the domestic clinic is progressing in an orderly manner. -007 is a brand-new anti-hepatitis B drug. Among similar target drugs in the world, its effectiveness, safety and research and development progress are in the first queue, and it is expected to cure hepatitis B through combined treatment.
"There are still seven months this year. Together with more than 23,000 cadres and employees of Qilu Pharmaceutical, I will get busy, move and run, and unswervingly move toward the goal of' a national pharmaceutical enterprise with world influence'. " Li Yan, president of Qilu Pharmaceutical Group, said.
Implant "green core"
Empower sustainable development
Qilu Pharmaceutical Biomedical Industrial Park is a "heavy weapon" for Jinan to develop its 100 billion biomedical industry, the largest strategic construction project invested by Qilu Pharmaceutical, and one of the largest and most technologically advanced biomedical industrial parks in China. The first thing to build industrial parks is energy conservation and environmental protection.
Lucid waters and lush mountains are invaluable assets. "Scientific and technological innovation, big data application, energy saving, low carbon and sustainable development" are the main directions for Qilu Pharmaceutical to actively implement the concept of green development and build a green factory.
Build a number of advanced intelligent systems, such as production intelligent control system, energy management and control platform, electric power automatic control system, etc. With intelligent control and big data application as the core, high-end technologies such as fuzzy prediction algorithm and cycle monitoring model are adopted to optimize the system control, thus ensuring the efficient operation of the system and realizing innovation and energy saving.
Make full use of clean new energy such as solar energy, air energy and geothermal energy, and green new equipment such as high-efficiency low-nitrogen burner, air suspension fan and hot-pressing distilled water machine to realize technical energy saving.
Make full use of waste heat and energy such as steam condensate, clean water, boiler exhaust and flue gas waste heat, continuously improve the comprehensive utilization efficiency of energy and realize energy saving.
Taking multiple measures simultaneously, Qilu Pharmaceutical's new and old kinetic energy conversion is implanted into the "energy-saving core". Since the 13th Five-Year Plan, the Group has achieved a total energy saving of 200,000 tons of standard coal, and was awarded the honorary titles of "Green Factory", "Advanced Energy Saving Unit in Shandong Province" and "Outstanding Contribution Unit in Jinan City" by the Ministry of Industry and Information Technology, Shandong Provincial Government and Jinan Municipal Government respectively.
Qilu Pharmaceutical (Inner Mongolia) Co., Ltd. Hulunbeier Branch's green bio-agricultural and veterinary drug poverty alleviation industrial project has a total investment of 3 billion yuan, of which the investment in environmental protection facilities accounts for 10.6 1% of the total investment, and the investment in safety facilities accounts for 1.07%. This is an example of the Group's continuous increase in EHS investment. In 20 19, the group invested 290 million yuan in environmental protection and 240 million yuan in environmental protection operation and maintenance. In the past three years, the group spent13.54 million yuan on environmental protection. Up to now, the accumulated investment in environmental protection infrastructure is160,000 yuan.
According to the concept of green development, Qilu Pharmaceutical has laid out the product structure of the Group in advance and gradually eliminated the backward production capacity. Through process screening, high-tech products with high standards, high technology content, high added value, low pollution and low energy consumption are taken as the research and development focus and applied to project planning. Using the design concept of smart factory, we can realize the automation of the whole production process, build a digital factory and pursue green and sustainable development.
Inner Mongolia Company invested 801.296 million yuan, added 2 1 sets of tail gas advanced treatment biological tower and 5 cyclone separators, installed 3 sets of fixed pollution source online monitoring system1set and 3 sets of VOC online monitoring system at factory boundary, which significantly improved the treatment effect of fermentation odor, greatly improved the treatment of odor inside and outside the factory boundary, and hired a third party to detect the odor concentration outside the factory boundary, all of which met the standards.
Group Shenghua Company invested 2 million yuan to use rake dryer to remove salt, reducing the total amount of salt discharged 100 tons/year. In addition, it also invested 7 million yuan to install RTO and activated carbon adsorption equipment for the regenerative incinerator, which reduced VOC emissions by 5 tons/year and greatly improved the production environment.
Hainan Company has built a new sewage treatment station with an area of 1 574.94 square meters and a total investment of 1 795 million yuan. The main structure is buried and does not occupy the above-ground space. Plant vegetation above the sewage treatment station and around the equipment room to reduce the influence of odor and noise. In this project, a deodorizing device is set up and led to the upper air for discharge, which avoids the influence of odor on the downwind direction. After completion and operation, it mainly treats the comprehensive wastewater generated by the whole plant. The reclaimed water can be reused 20,000 tons/year, which can be used for greening, saving about 20,000 tons of water annually, and the discharge index is far lower than the standard of Water Pollution Discharge Standard for Pharmaceutical Industry of Mixed Preparations (GB2 1908-2008) and other relevant requirements in Hainan Province.
Qifa Company eliminated coal-fired hot-blast stoves, invested more than 7.9 million yuan, replaced coal with clean energy such as electricity and steam, and newly installed 1 regenerative incinerator (RTO), which treated10.3 million m3 of malodorous waste gas from sewage treatment station every day, and used the waste heat generated by RTO to treat malodorous waste gas as a supplement to steam and electricity, thus achieving a double harvest of economic benefits and environmental protection benefits.
In 20 19, Antie invested13.5 million yuan to add RTO equipment for advanced treatment of waste gas in sewage treatment plant, which significantly improved the treatment effect of VOC and odor in sewage treatment plant, solved many years of sewage treatment problems, realized safety and stability, and greatly improved the working environment in production area. Hire the first one at the same time